Febuxostat

Literatur

• 1 Becker M A, Kisicki J, Khosravan R. et al . Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.  Nucleosides Nucleotides Nucleic Acids. 2004;  23 1111-1116
  Google Scholar
• 2 Becker M A, Schumacher H R, Espinoza L R. et al . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.  Arthritis Res Ther. 2010;  12 R63
  Google Scholar
• 3 Becker M A, Schumacher Jr H R, Wortmann R L. et al . Febuxostat compared with allopurinol in patients with hyperuricemia and gout.  N Engl J Med. 2005;  353 2450-2461
  Google Scholar
• 4 Becker M A, Schumacher Jr H R, Wortmann R L. et al . Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.  Arthritis Rheum. 2005;  52 916-923
  Google Scholar
• 5 Becker M A, Schumacher H R, MacDonald P A. et al . Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.  J Rheumatol. 2009;  36 1273-1282
  Google Scholar
• 6 EMA .Adenuric. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000777/WC500021812.pdf Stand Mai 2008
  Google Scholar
• 7 Emmerson B T. The management of gout.  N Engl J Med. 1996;  334 445-451
  Google Scholar
• 8 Fachinformation. Allopurinol. Stand April 2009. 
  Google Scholar
• 9 Fachinformation. Adenuric, Febuxostat. Stand Dez. 2009. 
  Google Scholar
• 10 FDA/CDER .Med. Review Febuxostat. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_MedR_P1.pdf bis http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_MedR_P5.pdf Stand Dez. 2008
  Google Scholar
• 11 Lee H Y, Ariyasinghe J T, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?.  Singapore Med J. 2008;  49 384-387
  Google Scholar
• 12 Moreland L W. Febuxostat – treatment for hyperuricemia and gout?.  N Engl J Med. 2005;  353 2505-2507
  Google Scholar
• 13 NICE .Febuxostat for the management of hyperuricaemia in people with gout. http://www.nice.org.uk/nicemedia/pdf/TA164Guidance.pdf Dez. 2008
  Google Scholar
• 14 Okamoto K, Eger B T, Nishino T. et al . An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.  J Biol Chem. 2003;  278 1848-1855
  Google Scholar
• 15 Okamoto K, Matsumoto K, Hille R. et al . The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.  Proc Natl Acad Sci U S A. 2004;  101 7931-7936
  Google Scholar
• 16 Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.  J Nippon Med Sch. 2008;  75 2-3
  Google Scholar
• 17 Reinders M K, Haagsma C, Jansen T L. et al . A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300 – 600 mg/day versus benzbromarone 100 – 200 mg/day in patients with gout.  Ann Rheum Dis. 2009;  68 892-897
  Google Scholar
• 18 Schumacher Jr H R. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.  Expert Opin Investig Drugs. 2005;  14 893-903
  Google Scholar
• 19 Schumacher Jr H R, Becker M A, Lloyd E. et al . Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.  Rheumatology (Oxford). 2009;  48 188-194
  Google Scholar
• 20 Schumacher Jr H R, Becker M A, Wortmann R L. et al . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.  Arthritis Rheum. 2008;  59 1540-1548
  Google Scholar
• 21 Takeda .US-amerikanische Produktinformation Uloric (Febuxostat). Stand Feb. 2009. 
  Google Scholar
• 22 Terkeltaub R. Update on gout: new therapeutic strategies and options.  Nat Rev Rheumatol. 2010;  6 30-38
  Google Scholar
• 23 Yu K H. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.  Recent Pat Inflamm Allergy Drug Discov. 2007;  1 69-75
  Google Scholar

Prof. Dr. med. Ali El-Armouche

Abteilung Pharmakologie
Universitätsmedizin Göttingen

Robert-Koch-Str. 40

37075 Göttingen

Phone: 0551/39-22602

Fax: 0551/39-5699

Email: ali.el-armouche@med.uni-goettingen.de